NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Forecast, Price & News $0.35 +0.01 (+3.11%) (As of 09/29/2023 08:52 PM ET) Add Compare Share Share Today's Range$0.34▼$0.3650-Day Range$0.28▼$0.7252-Week Range$0.28▼$1.51Volume19,300 shsAverage Volume74,767 shsMarket Capitalization$4.48 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cyclacel Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,155.4% Upside$8.00 Price TargetShort InterestBearish4.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.65) to ($3.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCyclacel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Cyclacel Pharmaceuticals has a forecasted upside of 2,155.4% from its current price of $0.35.Amount of Analyst CoverageCyclacel Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.24% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently increased by 6.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYCC. Previous Next 1.8 News and Social Media Coverage News SentimentCyclacel Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for CYCC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.92% of the stock of Cyclacel Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.33% of the stock of Cyclacel Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cyclacel Pharmaceuticals are expected to decrease in the coming year, from ($1.65) to ($3.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cyclacel Pharmaceuticals (NASDAQ:CYCC) StockCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Read More CYCC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCC Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Earns Sell Rating from Analysts at StockNews.comAugust 9, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.44 beats by $0.06, revenue of $0.37MOctober 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.August 9, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release Second Quarter 2023 Financial ResultsJuly 13, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's WhyJune 15, 2023 | forbes.comJointown Pharmaceutical GroupMay 26, 2023 | msn.comOppenheimer Maintains Cyclacel Pharmaceuticals (CYCC) Outperform RecommendationOctober 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.May 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax CreditMarch 8, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | msn.comOppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To KnowMarch 3, 2023 | msn.comA Preview Of Cyclacel Pharmaceuticals's EarningsJanuary 30, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor ConferenceDecember 15, 2022 | finance.yahoo.comCyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023November 9, 2022 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | msn.comEarnings Outlook For Cyclacel PharmaceuticalsNovember 7, 2022 | finance.yahoo.comHere's What to Expect Ahead of Wix's (WIX) Q3 Earnings ReleaseOctober 26, 2022 | finance.yahoo.comCyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022October 14, 2022 | fool.comCyclacel Pharmaceuticals (NASDAQ: CYCC)October 13, 2022 | finance.yahoo.comCyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR SymposiumAugust 11, 2022 | seekingalpha.comCyclacel stock rises 16% as net loss narrows, income growsJune 30, 2022 | finance.yahoo.comCyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor PatientsJune 30, 2022 | finance.yahoo.comCyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical PipelineMay 11, 2022 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | finance.yahoo.comCyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 10, 2022 | benzinga.comCyclacel Pharmaceuticals's Earnings OutlookSee More Headlines Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CYCC Company Calendar Last Earnings8/09/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCC CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees2,018Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+2,155.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,200,000.00 Net MarginsN/A Pretax Margin-7,578.55% Return on Equity-179.85% Return on Assets-97.98% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio2.27 Sales & Book Value Annual Sales$373,000.00 Price / Sales12.02 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book0.29Miscellaneous Outstanding Shares12,643,000Free Float11,642,000Market Cap$4.48 million OptionableNot Optionable Beta1.13 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 64)Pres, CEO & Exec. Director Comp: $763.55kMr. Paul McBarron (Age 62)Exec. VP of Fin., CFO, COO, Sec. & Exec. Director Comp: $394.68kDr. Mark H. Kirschbaum M.D. (Age 62)Sr. VP & Chief Medical Officer Comp: $523.84kMs. Gill Christie (Age 66)Director of HR Key CompetitorsZyVersa TherapeuticsNASDAQ:ZVSAGraybug VisionNASDAQ:GRAYBio-PathNASDAQ:BPTHEnsysce BiosciencesNASDAQ:ENSCSonoma PharmaceuticalsNASDAQ:SNOAView All CompetitorsInstitutional OwnershipSchonfeld Strategic Advisors LLCSold 71,261 shares on 8/14/2023Ownership: 5.259%View All Institutional Transactions CYCC Stock - Frequently Asked Questions Should I buy or sell Cyclacel Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares. View CYCC analyst ratings or view top-rated stocks. What is Cyclacel Pharmaceuticals' stock price forecast for 2023? 2 brokers have issued 1-year target prices for Cyclacel Pharmaceuticals' shares. Their CYCC share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 2,155.4% from the stock's current price. View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts. How have CYCC shares performed in 2023? Cyclacel Pharmaceuticals' stock was trading at $0.6670 on January 1st, 2023. Since then, CYCC shares have decreased by 46.8% and is now trading at $0.3547. View the best growth stocks for 2023 here. Are investors shorting Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 456,600 shares, an increase of 7.0% from the August 31st total of 426,900 shares. Based on an average daily trading volume, of 93,400 shares, the days-to-cover ratio is presently 4.9 days. Approximately 4.2% of the company's stock are short sold. View Cyclacel Pharmaceuticals' Short Interest. When is Cyclacel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our CYCC earnings forecast. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Wednesday, August, 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.10. The biotechnology company earned $0.37 million during the quarter. When did Cyclacel Pharmaceuticals' stock split? Shares of Cyclacel Pharmaceuticals reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO? 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA). What is Cyclacel Pharmaceuticals' stock symbol? Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC." How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cyclacel Pharmaceuticals' stock price today? One share of CYCC stock can currently be purchased for approximately $0.35. How much money does Cyclacel Pharmaceuticals make? Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $4.48 million and generates $373,000.00 in revenue each year. The biotechnology company earns $-21,200,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. How many employees does Cyclacel Pharmaceuticals have? The company employs 2,018 workers across the globe. How can I contact Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466. This page (NASDAQ:CYCC) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.